Loading...
Most analyses of bleeding associated with antithrombotic drugs have focused on gastrointestinal and intracranial hemorrhage. In contrast, in this study, researchers looked at risks for intraocular bleeding with various antithrombotic agents.
From a large U.S. insurance claims database, researchers identified 146,000 patients who began taking warfarin and 64,000 who began taking the direct-acting oral anticoagulants dabigatran (Pradaxa) or rivaroxaban (Xarelto) between 2010 and 2015 (apixaban [Eliquis] was not yet used widely during this interval). One-year risk for intraocular hemorrhage was similar in the warfarin and direct-anticoagulant groups (about 14 per 10,000 patients); however, after multivariate adjustment, risk was slightly lower …